Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial-Reference-Cited by-同舟云学术

Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial

Published:2021-05 Issue: Volume: Page:
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Caimi Paolo F,Ai Weiyun,Alderuccio Juan Pablo,Ardeshna Kirit M,Hamadani Mehdi,Hess Brian,Kahl Brad S,Radford John,Solh Melhem,Stathis Anastasios,Zinzani Pier Luigi,Havenith Karin,Feingold Jay,He Shui,Qin Yajuan,Ungar David,Zhang Xiaoyan,Carlo-Stella Carmelo

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: a longitudinal analysis of the National Cancer Data Base from 1998 to 2011;Al-Hamadani;Am J Hematol,2015

2. 2016 US lymphoid malignancy statistics by World Health Organization subtypes;Teras;CA Cancer J Clin,2016

3. Diffuse large B-cell lymphoma: optimizing outcome in the context of clinical and biologic heterogeneity;Sehn;Blood,2015

4. How I manage patients with relapsed/refractory diffuse large B cell lymphoma;Gisselbrecht;Br J Haematol,2018

5. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte;Feugier;J Clin Oncol,2005

Cited by 265 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exposure-Response–Based Multiattribute Clinical Utility Score Framework to Facilitate Optimal Dose Selection for Oncology Drugs;Journal of Clinical Oncology;2024-09-03

2. New and developing first line pharmacotherapies for treating non-Hodgkin lymphoma;Expert Opinion on Pharmacotherapy;2024-08-12

3. CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis;Blood;2024-08-08

4. SOHO State of the Art Updates and Next Questions | Contemporary Role of Autologous Stem Cell Transplantation for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the Era of Cellular Therapies;Clinical Lymphoma Myeloma and Leukemia;2024-08

5. Dermatologic toxicities of antibody-drug conjugates;Journal of the American Academy of Dermatology;2024-08